Evidence map›Paper›PMID 32170593›Full record

SynthesisInternational urology and nephrology2020

Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis.

Hatem Ali, Karim M Soliman, Ihab Shaheen, Jon Jin Kim, Mohsen El Kossi, Ajay Sharma, Ravi Pararajasingam, Ahmed Halawa

Abstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. ABO incompatibility in renal transplantation.World journal of transplantation · 2021
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Hatem AliDepartment of Renal Medicine, Royal Stoke University Hospital, NHS Foundation Trust, Stoke-on-Trent, UK.
Karim M SolimanDivision of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Ihab ShaheenFaculty of Medicine, Institute of Medical Sciences, University of Liverpool, Liverpool, UK.
Jon Jin KimFaculty of Medicine, Institute of Medical Sciences, University of Liverpool, Liverpool, UK.
Mohsen El KossiFaculty of Medicine, Institute of Medical Sciences, University of Liverpool, Liverpool, UK.
Ajay SharmaFaculty of Medicine, Institute of Medical Sciences, University of Liverpool, Liverpool, UK.
Ravi PararajasingamFaculty of Medicine, Institute of Medical Sciences, University of Liverpool, Liverpool, UK.
Ahmed HalawaFaculty of Medicine, Institute of Medical Sciences, University of Liverpool, Liverpool, UK. Ahmed.halawa@liverpool.nhs.uk.
University of Liverpool · GBDoncaster Royal Infirmary · GBMedical University of South Carolina · USRoyal Hospital for Children · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this meta-analysis is to explore the effect of IL-2RA vs rATG on the rate of acute rejection, post-transplant infections, and graft as well as patient's survival in standard- and high-risk renal transplant patients receiving tacrolimus-based maintenance immunotherapy.

methodsRandom effects model was the method used for identifying risk difference. Confidence interval including the value 1 was used as evidence for statistically significant risk difference. Heterogeneity was assessed using Der Simonian analysis. Heterogeneity was evident at the level of P value < 0.1

resultsThe random effects model showed no significant differences in both acute rejection rates between IL-2RA and rATG induction therapies with relative risk of 1.24 graft survival with relative risk 0.90. Patient survival also did not demonstrate any significant difference with a relative risk of 1.19. Random effects for CMV infection showed a lesser tendency for CMV infection in IL-2RA group compared to ATG group the with a relative risk of 0.73.In subgroup analysis, the random effects model for acute rejection rates in high-risk transplants showed a higher risk of acute rejection in the IL-2RA group compared to rATG (relative risk equals 1.55) In standard-risk transplants, there were no significant differences between both groups with relative risk equals 1.02

conclusionsThis meta-analysis revealed no significant difference in patient and graft survival when using IL-2RA vs rATG with the tacrolimus-based maintenance immunosuppression era. However, subgroup analysis showed less incidence of rejection in high-risk renal transplant recipient's population using rATG compared to IL-2RA.

Indexed as

Antilymphocyte SerumBasiliximabCytomegalovirus InfectionsDaclizumabGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsInduction ChemotherapyKidney TransplantationMaintenance ChemotherapyModels, StatisticalReceptors, Interleukin-2Survival RateTacrolimusAntilymphocyte SerumBasiliximabDaclizumabImmunosuppressive AgentsReceptors, Interleukin-2TacrolimusthymoglobulinCalcineurin inhibitorsInduction therapyOutcomesRenal transplantTacrolimus

Identifiers

PMID32170593
OpenAlexW3011676596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.